Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

COVAX

- PMLiVE

EMA to support real-world monitoring of COVID-19 treatments/vaccines

New infrastructure will support real-world studies

- PMLiVE

China’s CanSino Biologics reveals phase 2 coronavirus vaccine results

Candidate induced neutralising antibody responses

AstraZeneca AZ

AZ/Oxford’s COVID-19 vaccine proves promising in early trials

Vaccine candidate produced robust immune response

- PMLiVE

UK biotech Synairgen reveals promising early results for COVID-19 drug

Phase 1 results show drug cuts risk of developing severe disease by 79%

- PMLiVE

GSK agrees on 10% equity stake in mRNA specialist CureVac

Equity investment totals £130m with an upfront payment of £104m

- PMLiVE

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

Includes 15 medicines from company's generics division

- PMLiVE

Healthineers’ COVID-19 antibody test proves most effective in comparative study

Beats tests from Roche, Abbott and DiaSorin

- PMLiVE

Moderna’s COVID-19 vaccine produces immune response in early trial

Antibodies observed in all participants tested

- PMLiVE

Medicago doses first patients with plant-derived COVID-19 vaccine

Study will evaluate candidate alone or in combination with an adjuvant

- PMLiVE

FDA fast-tracks Pfizer/BioNTech’s COVID-19 vaccine candidates

Two investigational candidates granted accelerated review

- PMLiVE

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Also reveals new analyses from compassionate use programme

- PMLiVE

France’s Osivax raises over €30m for universal flu and coronavirus vaccines

Company’s technology designed to train immune system to recognise internal virus proteins

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links